Cybin Announces Closing of US$175 Million Registered Direct Offering

Cybin Inc., a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, has announced that it has closed its previously announced registered direct offering of 22,277,750 common shares in the capital of the company (a “Common Share”) and, in lieu of Common Shares to certain investors, 4,605,500 pre-funded Common Share purchase warrants (the “Pre-Funded Warrant”) at a price of US$6.51 per Common Share or Pre-Funded Warrant for aggregate gross proceeds of US$175,009,911.45.
 
Bennett Jones, together with Davis Polk as United States co-counsel, represented Jefferies, TD Cowen, Cantor Fitzgerald and Bloom Burton as placement agents.
 
The Bennett Jones team was led by Aaron Sonshine and Andrew Disipio (Capital Markets) and James Morand (Tax).
 
Read the transaction press release.